secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-105818
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax completes U.S. marketing authorization transfer to Sanofi for Nuvaxovid, earns $25M milestone
--------------------------------------------------------------------------------

- FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi on Nov 3, 2025.
- Second $25M milestone payment triggered; follows EU transfer in Oct 2025. Payment expected Q1 2026.
- Total non-dilutive capital secured YTD 2025 from Sanofi milestones is $225M.
- Sanofi now responsible for U.S. commercial and regulatory activities for Nuvaxovid.
- CEO John C. Jacobs notes delivery on partnership obligations and future royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925105818/0001104659-25-105818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925105818/tm2530132d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer